Toleranzia AB:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Toleranzia AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11213
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Toleranzia AB (Toleranzia) is a drug developer that utilizes immune system’s intrinsic power to treat autoimmune diseases. The company offers products and technologies including Re-Tolerogen for the treatment of autoimmune diseases. Its Re-Tolerogen platform technology is a fusion protein for the treatment of malfunctioning immune system. Toleranzia develops a treatment specifically for myasthenia gravis. The company’s technology enables production of drugs for the root cause of the disease symptoms, the mainstay of current treatments. It evaluates Re-Tolerogen treatment in animal models of rheumatoid arthritis, diabetes type 1, multiple sclerosis and an orphan condition. The company operates through academic institutions. It operates through its two offices in Gothenburg, Sweden. Toleranzia is headquartered in Gothenburg, Sweden.

Toleranzia AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Toleranzia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Toleranzia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Toleranzia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Toleranzia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Toleranzia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Toleranzia AB, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Toleranzia Enters into Agreement with Tecrea 10
Toleranzia Enters into Agreement with Leads to Development 11
Equity Offering 12
Toleranzia to Raise USD2.9 Million in Rights Offering of Shares 12
Toleranzia Raises USD2.4 Million in Rights Offering of Units 13
Toleranzia AB – Key Competitors 14
Toleranzia AB – Key Employees 15
Toleranzia AB – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Toleranzia AB, Pharmaceuticals & Healthcare, Key Facts 2
Toleranzia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Toleranzia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Toleranzia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Toleranzia AB, Deals By Therapy Area, 2012 to YTD 2018 8
Toleranzia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Toleranzia Enters into Agreement with Tecrea 10
Toleranzia Enters into Agreement with Leads to Development 11
Toleranzia to Raise USD2.9 Million in Rights Offering of Shares 12
Toleranzia Raises USD2.4 Million in Rights Offering of Units 13
Toleranzia AB, Key Competitors 14
Toleranzia AB, Key Employees 15
Toleranzia AB, Other Locations 16

List of Figures
Toleranzia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Toleranzia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Toleranzia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Toleranzia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Toleranzia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Toleranzia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Toleranzia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Toleranzia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Toleranzia AB:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cytodyn Inc (CYDY):企業の財務・戦略的SWOT分析
    Summary Cytodyn Inc (Cytodyn), formerly RexRay Corp, is a biotechnology company. It develops and commercializes monoclonal antibodies for the treatment of Human Immunodeficiency Virus (HIV) infections. It is investigating Leronlimab (PRO 140), a fully humanized IgG4 monoclonal antibody directed agai …
  • Juntendo University:製薬・医療:M&Aディール及び事業提携情報
    Summary Juntendo University (Juntendo) is a healthcare service provider that offers medical education and research programs and services. The university offers services such as medical education, practices and healthcare services including nursing, consultation, emergency room services, and others. …
  • Florida Power & Light Co:企業の発電所・SWOT分析2018
    Florida Power & Light Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Scottish and Southern Energy plc:企業の戦略・SWOT・財務分析
    Scottish and Southern Energy plc - Strategy, SWOT and Corporate Finance Report Summary Scottish and Southern Energy plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Archer Ltd (ARCHER):企業の財務・戦略的SWOT分析
    Archer Ltd (ARCHER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Ergomed Plc (ERGO):製薬・医療:M&Aディール及び事業提携情報
    Summary Ergomed Plc (Ergomed), formerly Ergomed Clinical Research Ltd is a drug development and clinical research services provider. The company provides service portfolio such as regulatory and quality management, biostatistics, study management, clinical data management, medical writing, and other …
  • Pacira Pharmaceuticals Inc (PCRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Pacira Pharmaceuticals Inc (Pacira) discovers, develops, manufactures and commercializes drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic indicated for infiltra …
  • TripAdvisor Inc:企業の戦略・SWOT・財務分析
    TripAdvisor Inc - Strategy, SWOT and Corporate Finance Report Summary TripAdvisor Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Metgasco Ltd (MEL):石油・ガス:M&Aディール及び事業提携情報
    Summary Metgasco Ltd (Metgasco) is an oil and gas exploration company. The company that acquires, explores, produces, and develops oil and gas, petroleum and hydrocarbon assets. It holds interests in Clarence Moreton Basin, an exploration license located in northern New South Wales. Metgasco supplie …
  • Power Finance Corporation Ltd.:企業の戦略・SWOT・財務情報
    Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Sumitomo Corporation:企業の戦略・SWOT・財務分析
    Sumitomo Corporation - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Suda Ltd (SUD)-製薬・医療分野:企業M&A・提携分析
    Summary Suda Ltd (Suda) is a drug delivery company that offers oro-mucosal administration solutions. The company’s products include artimist, zolpimist, SUD-001, SUD-002, SUD-003, SUD-004 and SUD-005. Its artimist is a sub-lingual spray for the treatment of p. falciparum severe paediatric malaria. S …
  • Vindhya Telelinks Ltd:企業の戦略・SWOT・財務情報
    Vindhya Telelinks Ltd - Strategy, SWOT and Corporate Finance Report Summary Vindhya Telelinks Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Leap Therapeutics Inc (LPTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Leap Therapeutics Inc (Leap Therapeutics), formerly HealthCare Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with cancer. The company’s pipeline products include DKN-01, a humanized monoclonal antibody that targets the D …
  • Texas A&M University-製薬・医療分野:企業M&A・提携分析
    Summary Texas A&M University (TAMU) is a research based university that offers educational and research services. The university provides undergraduate, graduate and professional courses to its students. It consists of various colleges and departments such as College of Agriculture and Life Sciences …
  • Tesco Plc (TSCO):企業の財務・戦略的SWOT分析
    Tesco Plc (TSCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Geistlich Pharma AG:企業の戦略的SWOT分析
    Geistlich Pharma AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Wyndham Destinations, Inc.:企業の戦略・SWOT・財務情報
    Wyndham Destinations, Inc. - Strategy, SWOT and Corporate Finance Report Summary Wyndham Destinations, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • C&A:戦略・SWOT・企業財務分析
    C&A - Strategy, SWOT and Corporate Finance Report Summary C&A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing …
  • Central Bank Of India:企業の戦略・SWOT・財務分析
    Central Bank Of India - Strategy, SWOT and Corporate Finance Report Summary Central Bank Of India - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆